logo
#

Latest news with #Bio-Rad

Bio-Rad price target lowered to $245 from $260 at Wells Fargo
Bio-Rad price target lowered to $245 from $260 at Wells Fargo

Business Insider

time9 hours ago

  • Business
  • Business Insider

Bio-Rad price target lowered to $245 from $260 at Wells Fargo

Wells Fargo lowered the firm's price target on Bio -Rad (BIO) to $245 from $260 and keeps an Equal Weight rating on the shares. The firm reduced estimates to reflect revised assumptions for life science growth in the second half of 2025 and 2026. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Bio-Rad's Management to Host Investor Meetings During Jefferies Global Healthcare Conference
Bio-Rad's Management to Host Investor Meetings During Jefferies Global Healthcare Conference

Yahoo

time29-05-2025

  • Business
  • Yahoo

Bio-Rad's Management to Host Investor Meetings During Jefferies Global Healthcare Conference

HERCULES, Calif., May 29, 2025--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company's Chief Operating Officer Jon DiVincenzo will host one-on-one meetings with investors during the Jefferies Global Healthcare Conference in New York City, on June 4, 2025. About Bio-Rad Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, Bio-Rad operates a global network of research, development, manufacturing, and sales operations with over 7,500 employees, and $2.6 billion in revenues in 2024. Our customers include universities, research institutions, hospitals, and biopharmaceutical companies, as well as clinical, food safety and environmental quality laboratories. Together, we develop innovative, high-quality products that advance science and save lives. To learn more, visit View source version on Contacts Investor Contact: Edward Chung, Investor Relations510-741-6104ir@ Media Contact: Anna Gralinska, Corporate Communications510-741-6643cc@ Sign in to access your portfolio

Bio-Rad's Management to Host Investor Meetings During Jefferies Global Healthcare Conference
Bio-Rad's Management to Host Investor Meetings During Jefferies Global Healthcare Conference

Business Wire

time29-05-2025

  • Business
  • Business Wire

Bio-Rad's Management to Host Investor Meetings During Jefferies Global Healthcare Conference

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company's Chief Operating Officer Jon DiVincenzo will host one-on-one meetings with investors during the Jefferies Global Healthcare Conference in New York City, on June 4, 2025. Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, Bio-Rad operates a global network of research, development, manufacturing, and sales operations with over 7,500 employees, and $2.6 billion in revenues in 2024. Our customers include universities, research institutions, hospitals, and biopharmaceutical companies, as well as clinical, food safety and environmental quality laboratories. Together, we develop innovative, high-quality products that advance science and save lives. To learn more, visit

Bio-Rad's Management to Participate in Fireside Chat During 2025 RBC Capital Markets Global Healthcare Conference
Bio-Rad's Management to Participate in Fireside Chat During 2025 RBC Capital Markets Global Healthcare Conference

Business Wire

time12-05-2025

  • Business
  • Business Wire

Bio-Rad's Management to Participate in Fireside Chat During 2025 RBC Capital Markets Global Healthcare Conference

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that its Chief Executive Officer Norman Schwartz and Chief Financial Officer Roop K. Lakkaraju will participate in a fireside chat event during the 2025 RBC Capital Markets Global Healthcare Conference on Wednesday, May 21, 2025, at 1:35 PM Eastern Time (10:35 AM Pacific Time). A live webcast and subsequent replay of the event will be available in the Investor Relations section of Bio-Rad's website at About Bio-Rad Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, Bio-Rad operates a global network of research, development, manufacturing, and sales operations with over 7,500 employees, and $2.6 billion in revenues in 2024. Our customers include universities, research institutions, hospitals, and biopharmaceutical companies, as well as clinical, food safety and environmental quality laboratories. Together, we develop innovative, high-quality products that advance science and save lives. To learn more, visit

Bio-Rad: Q1 Earnings Snapshot
Bio-Rad: Q1 Earnings Snapshot

Yahoo

time02-05-2025

  • Business
  • Yahoo

Bio-Rad: Q1 Earnings Snapshot

HERCULES, Calif. (AP) — HERCULES, Calif. (AP) — Bio-Rad Laboratories Inc. (BIO.B) on Thursday reported first-quarter earnings of $64 million. On a per-share basis, the Hercules, California-based company said it had profit of $2.29. Earnings, adjusted for non-recurring costs, came to $2.54 per share. The maker of instruments used in biomedical research posted revenue of $585.4 million in the period. Bio-Rad shares have dropped 28% since the beginning of the year. In the final minutes of trading on Thursday, shares hit $234.41, a decline of 19% in the last 12 months. _____ This story was generated by Automated Insights ( using data from Zacks Investment Research. Access a Zacks stock report on BIO.B at Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store